The good news for investors: There are steps to mitigate the damage now and avoid it in the future.

Turkish companies and individuals risk a battery of sanctions for providing Russia goods and services prohibited under Western export controls.

The country’s economy is caught between wary households and wobbly property firms, with no clear escape route.

The latest results exceed downbeat expectations, buying the cloud-software giant some reprieve from slowdown worries.

A combination of the two health insurers will be scrutinized by the government, but that doesn’t mean it won’t have a good argument at court.

The digital brokerage became synonymous with a new generation of investors in America. Now it wants to do the same in the U.K.

The deal could value CrownRock well above $10 billion including debt.

There are a host of tax breaks available to retirees and older Americans, but they’re easy to miss.

Stocks wavered Wednesday, dampening a November rally that has sent the S&P 500 toward its best month since July 2022.

A cash-and-stock deal between the health-insurance giants could be struck by year-end.

Few people have been wealthier, in all the senses of the word, than the brilliant billionaire investor.

Some analysts see the investor balances in money-market funds as a bullish sign for stocks and bonds.

The China megabank bought its U.S. broker-dealer 13 years ago for practically nothing. It got more than it bargained for.

New research tackles the source of financial conflict and what we can do about it.

Credit-card utilization and delinquency rates are on the rise.

Insiders and investors say the bank’s board, headed by Urs Rohner, was ultimately responsible for its fate.

The Dow rose more than 100 points in an abbreviated holiday session.

Several previously beaten-down sectors have been among the rally’s biggest gainers.

Binance’s landmark settlement with U.S. officials may clear the way for better exchange-traded funds based on the largest digital currency.

The first treatment based on the Nobel Prize-winning Crispr technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.

Smartphones and PCs will soon offer on-device AI capabilities as a major selling point. Will that spark a major sales cycle, or be just another overhyped feature?

The cases for and against putting a price on human organs go to the heart of the debate about capitalism.

U.S. stock markets were closed for the Thanksgiving holiday, global markets were muted and index futures edged higher.

Supercharged storms are bad for lending. Alabama-based Regions Financial is figuring out how to get ready.

The S&P 500 is on pace for its best month since July 2022.

The plea deal was a massive twist in the life of the industry’s most influential figurehead, Changpeng Zhao, who launched the online exchange in 2017 and developed it into a money-spinning trading machine.

Skeptics have had their prejudices reinforced. The two main use cases—fraud and crime—have been exposed in dramatic fashion.

U.S. crude oil and gasoline inventories increased more than expected last week while refinery capacity use rose from a week before.

A title insurance pilot program was scuttled after blowback from insurers and lawmakers.

With offshore wind projects bleeding cash, governments will have to pay more to hit their clean-energy targets. Recent auctions show just how much more.